Vaccinex, Inc.
(NASDAQ : VCNX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -3.01%152.520.0%$4782.73m
NVAXNovavax, Inc. -2.25%126.2592.9%$675.98m
BNTXBioNTech SE 1.11%120.000.0%$672.24m
AMGNAmgen, Inc. 1.01%229.211.3%$578.56m
GILDGilead Sciences, Inc. 1.15%61.561.0%$506.97m
BIIBBiogen, Inc. 0.73%245.871.7%$496.02m
REGNRegeneron Pharmaceuticals, Inc. -1.28%492.452.7%$472.10m
VRTXVertex Pharmaceuticals, Inc. 0.64%228.321.9%$455.95m
ILMNIllumina, Inc. 1.35%350.663.5%$426.07m
EXASEXACT Sciences Corp. 1.68%132.8719.6%$207.83m
SGENSeagen Inc. -0.52%179.235.8%$156.07m
BGNEBeiGene Ltd. 0.71%222.881.4%$141.27m
CRSPCRISPR Therapeutics AG 5.04%147.540.6%$137.84m
TXG10X Genomics, Inc. 2.63%149.040.0%$136.40m
SRNESorrento Therapeutics, Inc. 0.00%7.971.4%$136.15m

Company Profile

Vaccinex, Inc. is a clinical-stage biotechnology company, which engages in the development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses in the development of pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma and Huntington’s disease. Its products pipeline includes SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer and Deepak Sahasrabudhe in 1997 and is headquartered in Rochester, NY.